In this week’s video insight, David Buckland discusses the remarkable progress of Telix Pharmaceuticals (ASX:TLX). Over the past ten months, Telix’s share price has seen significant growth, driven by advancements in radiation imaging and therapy technologies. Their flagship product, Illuccix, is gaining traction in the market. With impressive revenue growth and strategic acquisitions, Telix Pharmaceuticals is well-positioned for continued success in the healthcare sector.
Subscribe to my insights: rogermontgomer...
Follow me!
Linkedin: / rogermontgomery
Facebook: / montgomeryroger
Twitter: / rjmontgomery